<DOC>
	<DOCNO>NCT01000857</DOCNO>
	<brief_summary>The primary purpose study compare steady-state pharmacokinetic profile paroxetine CR ( controlled-release ) dosage 25mg/day use propose final market tablet CR 25mg Japan standard paroxetine IR ( immediate-release ) dosage 20mg/day use currently market tablet IR 20mg Japan .</brief_summary>
	<brief_title>Repeat Dose Study Controlled-Release Paroxetine Tablets Immediate-Release Paroxetine Tablets Healthy Japanese Male Subjects</brief_title>
	<detailed_description>This study open , randomize , repeat dose , two-period crossover design Japanese healthy male volunteer . This clinical trial design primarily compare steady-state pharmacokinetic profile paroxetine CR dosage 25mg /day ( 25mg daily 14 day ) use propose final market tablet CR 25mg Japan paroxetine IR dosage 20mg/day ( 20mg daily 14 day ) use currently market IR 20mg tablet Japan , crossover oral repeat dose manner .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Healthy Japanese adult male 20 64 year age inclusive BMI 18.50 high &lt; 25.00 kg/m2 , bodyweight 50 kg high Nonsmokers AST , ALT , ALP , gammaGTP totalbilirubin upper limit normal range QTc ( B ) interval &lt; 450 msec Able attend visit complete study Capable give write informed consent , include compliance requirement restriction list consent form Any clinically relevant abnormality screen physical examination , vital sign , 12lead ECG and/or clinical laboratory test Medical history consider eligible inclusion study investigator Current chronic history liver disease , know hepatic biliary abnormality ( exception asymptomatic gallstone ) History psychiatric disorder suicide attempt behaviours History presence gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug History sensitivity paroxetine formulation , component thereof Positive urine drug screen Participation another clinical study postmarketing study subject expose investigational noninvestigational product device Participation clinical study postmarketing study investigational noninvestigational product device within 4 month precede first dose study medication History drug allergy , idiosyncrasy , exclude pollen allergy without current symptom History drug abuse , current condition drug abuse alcoholism History regular alcohol consumption exceed , average , 14 drinks/week ( 1 drink = 150 mL wine 350 mL beer 45 mL 80 proof distil spirit ) within 6 month screen Use prescription noprescription drug , include vitamin , crude drug , herbal dietary supplement ( include St John 's Wort ) within 14 day prior first dose study medication Unwillingness inability follow procedure outline protocol Consumption grapefruit grapefruitcontaining product 7 day prior first dose study medication Positive syphilis , HIV antibody antigen , Hepatitis B surface antigen , Hepatitis C antibody HTLV1 antibody Donation blood excess 400mL within previous 4 month 200mL within previous 1 month first dose study medication</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>controlled-release tablet</keyword>
	<keyword>repeat dose</keyword>
	<keyword>immediate-release tablet</keyword>
	<keyword>paroxetine</keyword>
	<keyword>safety</keyword>
	<keyword>crossover</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>steady-state</keyword>
	<keyword>Japanese healthy male volunteer</keyword>
	<keyword>tolerance</keyword>
</DOC>